UCSF Health’s new Cancer Immunotherapy Toxicity Evaluation (CITE) Program is a valuable resource for both patient care and provider consults. The only program of its kind in the Bay Area, our collaborative interprofessional team offers skilled consultative care for patients experiencing challenging immunotherapyrelated adverse events (irAEs), such as toxicities that are resistant to standard steroid treatment. The program also delivers peer-to-peer insight and second opinions for physicians and other providers concerned about acute or chronic immunotherapy toxicities in their patients, as well as guidance on safely maintaining or restarting immunotherapy.